Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients
Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
This study investigates an innovative treatment for recurrent ovarian cancer exploiting ex
vivo-generated allogeneic natural killer (NK) cells with or without preceding
non-myeloablative conditioning chemotherapy.